Thus, while the molecular profiling of NSCLC (including the EGFR testing) is considered a standard of care in the advanced setting, the utility and necessity of molecular testing in early stage NSCLC are currently coming under the spotlight. Here, EGFR is linked to non-small cell lung carcinoma.